Selinexor + Carfilzomib + Isatuximab + Dexamethasone for Multiple Myeloma

This trial explores a new combination of treatments to assess their safety and tolerability for people with multiple myeloma that has returned or not responded to previous treatments. The focus is on using selinexor (a potential new drug), carfilzomib, isatuximab, and dexamethasone together. The trial seeks participants who have tried at least one previous treatment for multiple myeloma and still show measurable signs of the disease. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new combination therapy.

The trial protocol does not specify if you must stop taking your current medications. However, you cannot take certain medications that affect the liver enzyme CYP3A4, like some antibiotics and herbal supplements, within 7 days before starting the trial. It's best to discuss your current medications with the trial team.

Research has shown that the combination of selinexor, carfilzomib, isatuximab, and dexamethasone appears safe. Studies have found that treatments using isatuximab are usually well-tolerated and effective. Specifically, when combined with other treatments, isatuximab can be safely administered using a special delivery system worn on the body.

Other research indicates that selinexor, when used with carfilzomib and dexamethasone, is generally safe for patients with multiple myeloma. However, these treatments can have side effects, and the specific combination under study is still being tested for safety.

Researchers are excited about the combination of Selinexor, Carfilzomib, Isatuximab, and Dexamethasone for multiple myeloma because it offers a novel approach by combining multiple mechanisms of action. Unlike standard treatments that often focus on a single pathway, this regimen combines Selinexor's unique ability to block cancer cells' survival signals with Carfilzomib's and Isatuximab’s targeted actions against the cancer cells themselves. This innovative blend aims to enhance treatment effectiveness and overcome resistance seen in conventional therapies. Additionally, the combination's potential to be administered both orally and intravenously provides flexibility in treatment delivery, potentially improving patient outcomes and quality of life.

Research has shown that a combination of four drugs—selinexor, carfilzomib, isatuximab, and dexamethasone—may help treat multiple myeloma, a type of blood cancer. One study found that 78% of patients with relapsed or hard-to-treat multiple myeloma responded to this treatment, with 44% experiencing a very good reduction in cancer activity. This indicates that many patients saw a significant decrease in their cancer. Another study demonstrated that selinexor can help myeloma cells that stopped responding to treatment become sensitive again. The success of these drugs in other situations supports their potential in this trial, where participants will receive the combination of selinexor, carfilzomib, isatuximab, and dexamethasone.¹⁴⁶⁷⁸